Novel and orally active 5-(1,3,4-oxadiazol-2-yl)pyrimidine derivatives as selective FLT3 inhibitors.

[1]  T. Naoe,et al.  A Novel FLT3 Inhibitor FI-700 Selectively Suppresses the Growth of Leukemia Cells with FLT3 Mutations , 2007, Clinical Cancer Research.

[2]  Nick Holford,et al.  Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics. , 2006, Blood.

[3]  Hemaka A. Rajapakse,et al.  A mild and efficient one pot synthesis of 1,3,4-oxadiazoles from carboxylic acids and acyl hydrazides , 2006 .

[4]  H. Kiyoi,et al.  Clinical Significance of FLT3 in Leukemia , 2005, International journal of hematology.

[5]  H. Döhner,et al.  A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. , 2005, Blood.

[6]  Brian S. Gerstenberger,et al.  tert-Buyldiphenylsilylethyl ("TBDPSE"): a practical protecting group for phenols. , 2005, The Journal of organic chemistry.

[7]  M. Levis,et al.  FLT3: ITDoes matter in leukemia , 2003, Leukemia.

[8]  T. Naoe,et al.  Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain , 2002, Oncogene.

[9]  T. Naoe,et al.  Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. , 2001, Blood.

[10]  G. A. Cain,et al.  Unsymmetrical 4,6-Diamino-2-methyl-5-nitropyrimidine Synthesis via 4,6-Bis(tosylates) , 2001 .

[11]  H. Saito,et al.  Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product , 1998, Leukemia.

[12]  N. F. Osborne,et al.  The Chemistry of Pseudomonic Acid.† 18. Heterocyclic Replacement of the α,β-Unsaturated Ester: Synthesis, Molecular Modeling, and Antibacterial Activity1 , 1997 .

[13]  D. Birnbaum,et al.  Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic cells. , 1993, Blood.

[14]  T. Bird,et al.  Characterization of the protein encoded by the flt3 (flk2) receptor-like tyrosine kinase gene. , 1993, Oncogene.

[15]  E. Estey,et al.  Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412 , 2004 .

[16]  J. Meslin,et al.  Cationic 1,3‐diazadienes in annulation reactions. Synthesis of pyrimidine, thiadiazinedioxide and triazine derivatives , 2001 .

[17]  P. Hodge,et al.  Protective groups in organic synthesis , 1981 .